Kriya Therapeutics is poised to revolutionize gene therapies for highly serious diseases like diabetes and severe obesity after landing a whopping $100 million in capital.
That’s on top of $80.5 million raised last year.
The biotech startup, with headquarters in Durham and Palo Alto, secured the Series B financing from Patient Square Capital.
Existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund. New investors included Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
The company said proceeds from the financing would be used to further “develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.”
Original Article Source: WRAL TechWire